Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6NYP

Crystal structure of UL144/BTLA complex

Summary for 6NYP
Entry DOI10.2210/pdb6nyp/pdb
DescriptorB- and T-lymphocyte attenuator, UL144, GLYCEROL, ... (7 entities in total)
Functional Keywordsimmune evasion protein, viral protein, immune system-viral protein complex, immune system/viral protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains8
Total formula weight103355.31
Authors
Aruna, B.,Zajonc, D.M.,Doukov, T. (deposition date: 2019-02-11, release date: 2019-05-29, Last modification date: 2024-10-16)
Primary citationBitra, A.,Nemcovicova, I.,Picarda, G.,Doukov, T.,Wang, J.,Benedict, C.A.,Zajonc, D.M.
Structure of human cytomegalovirus UL144, an HVEM orthologue, bound to the B and T cell lymphocyte attenuator.
J.Biol.Chem., 294:10519-10529, 2019
Cited by
PubMed Abstract: Human cytomegalovirus (HCMV) is a β-herpesvirus that has co-evolved with the host immune system to establish lifelong persistence. HCMV encodes many immunomodulatory molecules, including the glycoprotein UL144. UL144 is a structural mimic of the tumor necrosis factor receptor superfamily member HVEM (herpesvirus entry mediator), which binds to the various ligands LIGHT, LTα, BTLA, CD160, and gD. However, in contrast to HVEM, UL144 only binds BTLA, inhibiting T-cell activation. Here, we report the crystal structure of the UL144-BTLA complex, revealing that UL144 utilizes residues from its N-terminal cysteine-rich domain 1 (CRD1) to interact uniquely with BTLA. The shorter CRD2 loop of UL144 also alters the relative orientation of BTLA binding with both N-terminal CRDs. By employing structure-guided mutagenesis, we have identified a mutant of BTLA (L123A) that interferes with HVEM binding but preserves UL144 interactions. Furthermore, our results illuminate structural differences between UL144 and HVEM that explain its binding selectivity and highlight it as a suitable scaffold for designing superior, immune inhibitory BTLA agonists.
PubMed: 31126984
DOI: 10.1074/jbc.RA119.009199
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.7 Å)
Structure validation

250835

PDB entries from 2026-03-18

PDB statisticsPDBj update infoContact PDBjnumon